<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34319865</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.</ArticleTitle>
        <Pagination>
          <StartPage>1942712</StartPage>
          <MedlinePgn>1942712</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1942712</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2021.1942712</ELocationID>
        <Abstract>
          <AbstractText Label="UNLABELLED">In Sweden, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2009 and replaced by the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) or the 13- valent PCV (PCV13) from late 2009. We assessed the impact of PCVs on rates of antibiotic prescribing, tympanostomy tube placement (TTP), and healthcare resource utilization and direct costs of physician- diagnosed otitis media/acute otitis media (OM) in children ≤2 years of age living in Skåne (PCV7 then PHiD- CV) or Västra Götalandsregionen (VGR; PCV7 then PCV13). Retrospective cohort study using linked patient- level data from national and regional (Skåne and VGR) healthcare databases in Sweden from July 1, 2005, to December 31, 2013 (NCT02742753). Descriptive time-series analyses showed antibiotic prescriptions and TTP incidence declined after PHiD-CV/PCV13 introduction versus the pre-PCV period. The annualized mean frequencies of antibiotic use, primary care visits, outpatient visits, TTP and myringotomy procedures all decreased after PHiD-CV/PCV13 compared with pre-PCV cohorts. Annualized mean total OM-associated healthcare costs decreased in the PCV7 versus pre-PCV cohorts by 20.0% in Skåne and 10.2% in VGR, and further declined in the PHiD-CV and PCV13 cohorts (20.7% and 15.3%, respectively, relative to the PCV7 cohort), although the duration of PCV7 use differed between regions. Decreases in adjusted annualized cost ratios between cohorts per child susceptible to OM were statistically significant after PCV7 introduction and again with either PHiD-CV or PCV13 introduction in both regions. Following sequential PCV introduction, OM-related healthcare utilization and associated costs decreased in the study regions in Sweden.</AbstractText>
          <AbstractText Label="PLAIN LANGUAGE SUMMARY"><b>What is the context?</b>Otitis media is one of the most frequent reasons for healthcare visits and antibiotic use among young children. Although it is considered as a mild illness, the overall economic burden is substantial due to its high frequency.Otitis media can be caused by different bacteria including Streptococcus pneumoniae, which is also responsible for pneumonia and meningitis. Pneumococcal conjugate vaccines Prevenar (Pfizer Inc.), Synflorix (GSK), and Prevenar 13 (Pfizer Inc.) protect against pneumococcal diseases and reduce its occurrence.However, it is not known how the routine use of these vaccines may affect otitis media-related healthcare resources and costs.<b>What is new?</b>In this study, we assessed trends in rates of healthcare utilization and associated costs due to otitis media in young children before (2005-2008) and after (2009-2013) use of pneumococcal conjugate vaccines. The study was conducted in two Swedish regions; one used Prevenar then Synflorix, while the other used Prevenar then Prevenar 13.We found that compared to the period before pneumococcal conjugate vaccine implementation, the postpneumococcal conjugate vaccine period was associated with:<b>What is the impact on current thinking?</b>The use of pneumococcal conjugate vaccines effectively reduces healthcare utilization and resources associated with otitis mediaThis indirect effect on the reduction of otitis media burden provides further benefit to the implementation of pneumococcal vaccination.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Edmondson-Jones</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-1113-8008</Identifier>
            <AffiliationInfo>
              <Affiliation>Parexel International, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dibbern</LastName>
            <ForeName>Therese</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0003-0645-1550</Identifier>
            <AffiliationInfo>
              <Affiliation>Parexel International, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hultberg</LastName>
            <ForeName>Marcus</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-0541-0538</Identifier>
            <AffiliationInfo>
              <Affiliation>Parexel International, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anell</LastName>
            <ForeName>Bengt</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-3822-7628</Identifier>
            <AffiliationInfo>
              <Affiliation>Parexel International, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Medin</LastName>
            <ForeName>Emma</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-7327-7954</Identifier>
            <AffiliationInfo>
              <Affiliation>Parexel International, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-4470-6411</Identifier>
            <AffiliationInfo>
              <Affiliation>GSK, Wavre, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Talarico</LastName>
            <ForeName>Carla</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-9107-5873</Identifier>
            <AffiliationInfo>
              <Affiliation>GSK, Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000069443">Heptavalent Pneumococcal Conjugate Vaccine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D022242">Pneumococcal Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018074">Vaccines, Conjugate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069443" MajorTopicYN="N">Heptavalent Pneumococcal Conjugate Vaccine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010033" MajorTopicYN="Y">Otitis Media</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011008" MajorTopicYN="Y">Pneumococcal Infections</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022242" MajorTopicYN="N">Pneumococcal Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018074" MajorTopicYN="N">Vaccines, Conjugate</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Cost</Keyword>
        <Keyword MajorTopicYN="Y">Sweden</Keyword>
        <Keyword MajorTopicYN="Y">antibiotics</Keyword>
        <Keyword MajorTopicYN="Y">otitis media</Keyword>
        <Keyword MajorTopicYN="Y">pneumococcal conjugate vaccines</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>28</Day>
          <Hour>17</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34319865</ArticleId>
        <ArticleId IdType="pmc">PMC8920213</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2021.1942712</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Auinger P, Lanphear BP, Kalkwarf HJ, Mansour ME.. 
Trends in otitis media among children in the United States. Pediatrics. 2003;112:514–20. doi:10.1542/peds.112.3.514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.112.3.514</ArticleId>
            <ArticleId IdType="pubmed">12949276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGrath LJ, Becker-Dreps S, Pate V, Brookhart MA.. 
Trends in antibiotic treatment of acute otitis media and treatment failure in children, 2000-2011. PLoS One. 2013;8:e81210. doi:10.1371/journal.pone.0081210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0081210</ArticleId>
            <ArticleId IdType="pmc">PMC3852237</ArticleId>
            <ArticleId IdType="pubmed">24324680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monasta L, Ronfani L, Marchetti F, Montico M, Vecchi Brumatti L, Bavcar A, Grasso D, Barbiero C, Tamburlini G. Burden of disease caused by otitis media: systematic review and global estimates. PLoS One. 2012;7:e36226. doi:10.1371/journal.pone.0036226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0036226</ArticleId>
            <ArticleId IdType="pmc">PMC3340347</ArticleId>
            <ArticleId IdType="pubmed">22558393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tong S, Amand C, Kieffer A, Kyaw MH. Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008-2014. BMC Health Serv Res. 2018;18:318.doi. doi:10.1186/s12913-018-3139-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12913-018-3139-1</ArticleId>
            <ArticleId IdType="pmc">PMC5932897</ArticleId>
            <ArticleId IdType="pubmed">29720156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur R, Morris M, Pichichero ME. Epidemiology of acute otitis media in the postpneumococcal conjugate vaccine era. Pediatrics. 2017;140:e20170181. doi:10.1542/peds.2017-0181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2017-0181</ArticleId>
            <ArticleId IdType="pmc">PMC5574724</ArticleId>
            <ArticleId IdType="pubmed">28784702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vergison A, Dagan R, Arguedas A, Bonhoeffer J, Cohen R, Dhooge I, Hoberman A, Liese J, Marchisio P, Palmu AA, et al. Otitis media and its consequences: beyond the earache. Lancet Infect Dis. 2010;10:195–203. doi:10.1016/s1473-3099(10)70012-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1473-3099(10)70012-8</ArticleId>
            <ArticleId IdType="pubmed">20185098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenfeld RM, Schwartz SR, Pynnonen MA, Tunkel DE, Hussey HM, Fichera JS, Grimes AM, Hackell JM, Harrison MF, Haskell H, et al. Clinical practice guideline: tympanostomy tubes in children. Otolaryngol Head Neck Surg. 2013;149:S1–35. doi:10.1177/0194599813487302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0194599813487302</ArticleId>
            <ArticleId IdType="pubmed">23818543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ngo CC, Massa HM, Thornton RB, Cripps AW. Predominant bacteria detected from the middle ear fluid of children experiencing otitis media: a systematic review. PLoS One. 2016;11:e0150949. doi:10.1371/journal.pone.0150949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0150949</ArticleId>
            <ArticleId IdType="pmc">PMC4783106</ArticleId>
            <ArticleId IdType="pubmed">26953891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency . Synflorix product information [internet]. [accessed
2018. 
Dec
06]. https://www.ema.europa.eu/documents/product-information/synflorix-epar-product-information_en.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Clarke C, Bakaletz LO, Ruiz-Guinazu J, Borys D, Mrkvan T. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage. Expert Rev Vaccines. 2017;16:1–14. doi:10.1080/14760584.2017.1333905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14760584.2017.1333905</ArticleId>
            <ArticleId IdType="pubmed">28571504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liese JG, Silfverdal SA, Giaquinto C, Carmona A, Larcombe JH, Garcia-Sicilia J, Fuat A, Garces-Sanchez M, Basanta MLA, Hiraldo EM, et al. Incidence and clinical presentation of acute otitis media in children aged &lt;6 years in European medical practices. Epidemiol Infect. 2014;142:1778–88. doi:10.1017/S0950268813002744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S0950268813002744</ArticleId>
            <ArticleId IdType="pmc">PMC4071996</ArticleId>
            <ArticleId IdType="pubmed">24330917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Public Health Agency of Sweden . Vaccinationsstatistik från Barnavårdcentraler [internet]. [accessed 2017 Dec
18]. www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistikdatabaser-och-visualisering/vaccinationsstatistik/statistik-fran-barnavardcentraler/.</Citation>
        </Reference>
        <Reference>
          <Citation>Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Clin Infect Dis. 2014;59:1724–32. doi:10.1093/cid/ciu683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciu683</ArticleId>
            <ArticleId IdType="pubmed">25159581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lau W, Murray M, El-Turki A, Saxena S, Ladhani S, Long P, Sharland M, Wong ICK, Hsia Y. Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom. Vaccine. 2015;33:5072–79. doi:10.1016/j.vaccine.2015.08.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2015.08.022</ArticleId>
            <ArticleId IdType="pubmed">26297875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Littorin N, Ahl J, Udden F, Resman F, Riesbeck K. Reduction of Streptococcus pneumoniae in upper respiratory tract cultures and a decreased incidence of related acute otitis media following introduction of childhood pneumococcal conjugate vaccines in a Swedish county. BMC Infect Dis. 2016;16:407. doi:10.1186/s12879-016-1750-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12879-016-1750-5</ArticleId>
            <ArticleId IdType="pmc">PMC4982432</ArticleId>
            <ArticleId IdType="pubmed">27514843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eythorsson E, Hrafnkelsson B, Erlendsdottir H, Gudmundsson SA, Kristinsson KG, Haraldsson A. Decreased acute otitis media with treatment failure after introduction of the ten-valent pneumococcal Haemophilus influenzae Protein D conjugate vaccine. Pediatr Infect Dis J. 2018;37:361–66. doi:10.1097/inf.0000000000001870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/inf.0000000000001870</ArticleId>
            <ArticleId IdType="pubmed">29278616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmu AA, Rinta-Kokko H, Nohynek H, Nuorti JP, Jokinen J. Impact of national ten-valent pneumococcal conjugate vaccine program on reducing antimicrobial use and tympanostomy tube placements in Finland. Pediatr Infect Dis J. 2018;37:97–102. doi:10.1097/inf.0000000000001810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/inf.0000000000001810</ArticleId>
            <ArticleId IdType="pubmed">29088026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edmondson-Jones M, Dibbern T, Hultberg M, Anell B, Medin E, Feng Y, Talarico C. The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions. Hum Vaccin Immunother. 2021;17:517–26. doi:10.1080/21645515.2020.1775455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21645515.2020.1775455</ArticleId>
            <ArticleId IdType="pmc">PMC7899701</ArticleId>
            <ArticleId IdType="pubmed">32574101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M, et al. The new Swedish prescribed drug register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726–35. doi:10.1002/pds.1294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pds.1294</ArticleId>
            <ArticleId IdType="pubmed">16897791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Box G, Jenkins G. Time series analysis, forecasting and control. San Francisco:  (CA): Holden-Day; 1976.</Citation>
        </Reference>
        <Reference>
          <Citation>Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc Natl Acad Sci USA. 2018;115:12896–901. doi:10.1073/pnas.1721095115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1721095115</ArticleId>
            <ArticleId IdType="pmc">PMC6304973</ArticleId>
            <ArticleId IdType="pubmed">30559195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341–48. doi:10.1056/NEJMoa035060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa035060</ArticleId>
            <ArticleId IdType="pubmed">14523142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen R, Levy C, de La Rocque F, Gelbert N, Wollner A, Fritzell B, Bonnet E, Tetelboum R, Varon E. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J. 2006;25:1001–07. doi:10.1097/01.inf.0000243163.85163.a8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.inf.0000243163.85163.a8</ArticleId>
            <ArticleId IdType="pubmed">17072121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiese AD, Huang X, Yu C, Mitchel EF, Kyaw MH, Griffin MR, Grijalva CG. Changes in otitis media episodes and pressure equalization tube insertions among young children following introduction of the 13-valent pneumococcal conjugate vaccine: a birth-cohort based study. Clin Infect Dis. 2019;69:2162–69. doi:10.1093/cid/ciz142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciz142</ArticleId>
            <ArticleId IdType="pubmed">30770533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gisselsson-Solen M. Trends in otitis media incidence after conjugate pneumococcal vaccination: a national observational study. Pediatr Infect Dis J. 2017;36:1027–31. doi:10.1097/inf.0000000000001654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/inf.0000000000001654</ArticleId>
            <ArticleId IdType="pubmed">28657970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>By A, Sobocki P, Forsgren A, Silfverdal SA. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model. Clin Ther. 2012;34:177–89. doi:10.1016/j.clinthera.2011.12.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2011.12.007</ArticleId>
            <ArticleId IdType="pubmed">22284997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyrstrup M, Beckman A, Molstad S, Engstrom S, Lannering C, Melander E, Hedin K. Reduction in antibiotic prescribing for respiratory tract infections in Swedish primary care- a retrospective study of electronic patient records. BMC Infect Dis. 2016;16:709. doi:10.1186/s12879-016-2018-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12879-016-2018-9</ArticleId>
            <ArticleId IdType="pmc">PMC5124268</ArticleId>
            <ArticleId IdType="pubmed">27887585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wasserman M, Sings HL, Jones D, Pugh S, Moffatt M, Farkouh R. Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Rev Vaccines. 2018;17:71–78. doi:10.1080/14760584.2018.1409116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14760584.2018.1409116</ArticleId>
            <ArticleId IdType="pubmed">29164952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perdrizet J, Lai YS, Williams S, Struwig VA, Wasserman M. Retrospective impact analysis and cost-effectiveness of the pneumococcal conjugate vaccine infant program in Australia. Infect Dis Ther. 2021;10:507–20. doi:10.1007/s40121-021-00409-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40121-021-00409-7</ArticleId>
            <ArticleId IdType="pmc">PMC7954941</ArticleId>
            <ArticleId IdType="pubmed">33575966</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
